Sorrento Therapeutics, Inc.

Equities

SRNE

US83587F2020

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
0.009 ^USD	-10.00%		-18.18%	-92.71%

Apr. 10	Sorrento Therapeutics, Inc. Emerged from Bankruptcy	CI
Mar. 15	Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	MT

SORRENTO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

January 20, 2022 at 09:04 am EST

Item 8.01. Other Events.

On January 20, 2022, Sorrento Therapeutics, Inc. (the "Company") issued a press release announcing the release of new data on the Omicron variant neutralizing antibody (nAb) STI-9167, COVISHIELD, an advanced stage antibody discovered and developed for clinical trials in an ongoing collaboration between immunologists and virologists at the Company and the Icahn School of Medicine at Mount Sinai in New York, NY. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibit.



  99.1     Press Release, dated January 20, 2022.
104      Cover Page Interactive Data File, formatted in Inline Extensible
         Business Reporting Language (iXBRL).

Latest news about Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Emerged from Bankruptcy	Apr. 10	CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	Mar. 15	MT
Final DIP Financing Approved for Sorrento Therapeutics, Inc.	Mar. 12	CI
Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.	Mar. 11	CI
Motion for Asset Sale Approved for Sorrento Therapeutics, Inc.	Mar. 07	CI
Interim DIP Financing Approved for Sorrento Therapeutics, Inc.	Feb. 29	CI
Health Care Slips on Growth Doubts -- Health Care Roundup	Feb. 26	DJ
Motion for Case Dismissal Filed for Sorrento Therapeutics, Inc.	Feb. 08	CI
Sixth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	Feb. 04	CI
Fifth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	Dec. 17	CI
Second Modified Joint Liquidation Plan and DIscllosure Statement Approved for Sorrento Therapeutics, Inc.	Nov. 30	CI
Sorrento Therapeutics, Inc. Completes Reduction in U.S. Headcount from 123 to 90	Nov. 07	CI
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Chief Financial Officer	Nov. 07	CI
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Its Executive Vice President	Nov. 07	CI
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million.	Nov. 02	CI
Motion for Asset Sale Filed by Sorrento Therapeutics, Inc.	23-10-30	CI
Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors	23-10-27	CI
Combined Hearing for Disclosure Statement and Plan Approved for Sorrento Therapeutics, Inc.	23-10-18	CI
Fourth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	23-10-18	CI
Joint Liquidation Plan and Disclosure Statement Filed by Sorrento Therapeutics, Inc.	23-10-11	CI
Third Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	23-10-05	CI
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics	23-09-21	MT
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q).	23-09-20	CI
Scilex Holding's Phase 2 Trial Shows Safety, Efficacy of Treatment for Lower Back Pain	23-09-14	MT
Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso	23-09-12	CI

Chart Sorrento Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Companyâs segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Companyâs immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
SORRENTO THERAPEUTICS, INC.	-92.71%	4.89M
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.79%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-14.22%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs